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Hepatocellular carcinoma (HCC) is a fatal disease and ranked fifth in cancer
related mortality. Persistent activation of NF-κB is responsible for the oncogenesis,
metastasis, tumor evasion, anti-apoptosis, angiogenesis and proliferation in HCC.
Therefore, designing of chemically novel, biologically potent small molecules that
target NF-κB signaling cascade have gained prominent clinical interest. Herein we
synthesized a novel class of 4-(substituted)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one by
reacting 2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one with various alkyl halides by using
combustion derived bismuth oxide. We evaluated the antiproliferative efficacy of
newly synthesized compounds against HCC cells and identified 4-(4-nitrobenzyl)-2H-
pyrido[3,2-b][1,4]oxazin-3(4H)-one (NPO) as lead anticancer agent. In addition, we
investigated the effect of NPO on the DNA binding ability of NF-κB and NF-κB regulated
luciferase expression in HCC cells. The results demonstrated that NPO can induce
significant growth inhibitory effects in HepG2, HCCLM3 and Huh-7 cells in dose
and time-dependent manner. Interestingly, NPO induced significant downregulation in
p65 DNA binding ability, p65 phosphorylation and subsequent expression of NF-κB
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dependent luciferase gene expression in diverse HCC cell lines. Further, in silico docking
analysis suggested that NPO can show direct physical interaction with NF-κB. Finally,
NPO was found to significantly abrogate tumor growth at a dose of 50 mg/kg in an
orthotopic mouse model. Thus, we report the potential anticancer effects of NPO as a
novel inhibitor of NF-κB signaling pathway in HCC.
Keywords: oxazines, anticancer, NF-κB, hepatocellular carcinoma, apoptosis
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the leading
common cancers threatening the globe with high mortality
rate (Subramaniam et al., 2013; Bharathkumar et al., 2014; Dai
et al., 2015; Swamy et al., 2017). HCC ranks fifth most common
cancer in men and ninth in women with high mortality rate
all over the world (Flores and Marrero, 2014; Ashtari et al.,
2015; Ferlay et al., 2015; Dai et al., 2016). Alcoholic hepatitis,
non-alcoholic steatohepatitis, endemic hepatitis B or C viral
infections, hemochromatosis, obesity, and consumption of
aflatoxin B1 remains as the major factors contributing to the
development of HCC (Subramaniam et al., 2013; Mohan et al.,
2014). Moreover, HCC is often diagnosed at advanced stages
in which the currently available therapeutic agents exhibit
limited efficacy and contribute to poor prognosis (Chen et al.,
2015). However, early detection and development of new
therapeutics can contribute to improved prognosis in HCC
patients.
Nuclear factor kappa B (NF-κB) is a latent pro-inflammatory
transcription factor identified by Baltimore and colleagues in
1986 and distributed enormously in the cytoplasm of most
of the mammalian cells (Ahn et al., 2007; Sethi et al.,
2007, 2012; Shin et al., 2014; Neelgundmath et al., 2015;
Puar et al., 2018). Depending on the cell type and cellular
environment, various ligands including TNF-α, IL-1β, LTβ,
LPS, CD40L, and BAFF relay signal for the activation of NF-
κB (Sethi et al., 2006; Dey et al., 2008; Li et al., 2015b). In
the absence of activation by various ligands, NF-κB remains
associated with inhibitory-κB (IκB) in the cytoplasm (Li and
Sethi, 2010; Manu et al., 2011; Chai et al., 2015; Puar et al.,
2018). The interaction of specific ligand with its receptor
triggers the activation of upstream kinases that can lead to
the phosphorylation, ubiquitination and degradation of IκB and
thereby activation of NF-κB which can translocate into nucleus
(Sethi and Tergaonkar, 2009; Samy et al., 2012; Keerthy et al.,
2014; Manu et al., 2014; Mohan et al., 2018). NF-κB also
regulates the expression of nearly five hundred genes which
are essential for the maintenance of homeostatic condition
and promotion of oncogenesis (Gupta et al., 2010; Li et al.,
2013, 2015a; Manu et al., 2015; Ningegowda et al., 2017).
Persistent activation of NF-κB has been reported in several
pro-inflammatory diseases including cancers, ulcerative colitis,
Crohn’s disease, asthma and rheumatoid arthritis (Yamamoto
and Gaynor, 2001; Aggarwal and Harikumar, 2009; Manu
et al., 2012). Thus, designing novel NF-κB inhibitors may
provide a promising therapeutic approach for the treatment of
HCC.
The anti-tumor potential of oxazine-based compounds have
been studied extensively in several cancer models and they
have been reported to exhibit significant activity both in vitro
and in vivo (Basappa Murugan et al., 2010; Bharathkumar
et al., 2015). We have previously reported the in vitro NF-κB
inhibitory activity of novel oxazines in colon cancer cells
and in vivo inflammatory bowel disease model (Nirvanappa
et al., 2016). In another study, 2-ethoxy-4,5-diphenyl-1,3-
oxazine-6-one was reported to downregulate nuclear NF-κB in
NGF-differentiated PC12 cells induced with lipopolysaccharide
(Ansari et al., 2011). In addition, oxazine-tocotrienol conjugates
have been demonstrated to decrease phosphorylation of NF-κB
and IκB in + SA mammary tumor growth in syngeneic mice
(Ananthula et al., 2014). Furthermore, it has been reported
that derivatives of 1,3-oxazine and 1,3-benzoxazine show
potent anticancer activity against lung and colon cancer cells.
3,5-Bis(2-pyridinylmethylidene)-4-piperidone, a pyridine
derivative was reported to act as a potent inhibitor of LPS-
induced NF-κB DNA binding activity (Olivera et al., 2012).
Overall, these studies suggest that oxazines and pyridine-based
small molecules could serve as important therapeutic agents
to target various malignancies. Therefore, in continuation
of our efforts to synthesize and explore medicinal properties
of various heterocyclic compounds (Rangappa and Basappa,
2005; Srinivas et al., 2015; Anusha et al., 2016; Mohan et al.,
2016, 2018; Sebastian et al., 2016), in the present article,
we have reported the synthesis of pyrido-1,4-oxazin-3-ones
and have also examined their anticancer potential against
panel of HCC cells. Additionally, we have identified 4-(4-
nitrobenzyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one (5e, NPO)
can function as potent anticancer agent and demonstrated
its potential effects on cell viability, apoptosis, NF-κB
activation in HCC cells and tumor growth in preclinical
mouse model.
MATERIALS AND METHODS
Chemistry
All chemicals used were of analytical grade and purchased from
Sigma Aldrich, and SRL, Mumbai (India). 1H NMR spectra were
recorded on a Agilent (400 MHz) spectrometer in CDCl3 solvent,
using TMS as an internal standard, 13C NMR spectra were
recorded on a Agilent (100 MHz) spectrometer and chemical
shifts were expressed as δ ppm and abbreviations are assigned as,
s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet
and J values are given in Hz. Mass spectra were determined on
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a Shimadzu LC-MS, elemental analyses were carried out using
an Elemental Vario Cube CHNS Rapid Analyzer. Progress of the
reaction was monitored by TLC pre-coated silica gel plates.
General Procedure for the Synthesis of
N-Substituted Pyrido-1,4-Oxazin-3-Ones
N-substituted pyrido-1,4-oxazin-3-ones were prepared in two
step reaction. Initially, 2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
was prepared as described earlier (Ankalgi and Ranawat, 2012).
In brief, 2-aminopyridine-3-ol (1) was made to react with
chloroacetylchloride (2) at 5◦C in basic medium to generate 2H-
pyrido[3,2-b][1,4]oxazin-3(4H)-one (3). In the next step, mixture
of 2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one(3), benzyl halide(4)
and combustion derived bismuth oxide (1.5 mmol) was taken
in a 50 ml round bottom flask and stirred for 5 h in DMF
solvent at 40◦C. Progress of the reaction was monitored by
TLC. After completion of the reaction, catalyst was filtered
followed by the addition of water to the filtrate. Thereafter, final
compound is extracted using ethyl acetate, washed with brine
solution, dried with anhydrous sodium sulfate and concentrated
using rotary evaporator. The title compounds are purified by
column chromatography using ethyl acetate and hexane as
eluent. Combustion derived Bi2O3was prepared using previously
reported protocol from our laboratory (Anusha et al., 2014).
4′-((3-Oxo-2H-Pyrido[3,2-b][1,4]Oxazin-
4(3H)-yl)Methyl)-[1,1′-Biphenyl]-2-
Carbonitrile (5a)
Compound 5a was prepared from pyrido1,4-oxazin-3-one
3 (1mmol), 4′-(bromomethyl)-[1,1′-biphenyl]-2-carbonitrile 4a
(1.2 mmol) and combustion derived bismuth oxide, yield 97%,
melting point 134–136◦C, Elemental analysis calculated for
C21H15N3O2: C, 73.89; H, 4.43; N, 12.31; found C, 73.64;
H, 4.51; N, 12.23%; 1H NMR (CDCl3, 400 MHz) δ:8.04-
8.02(d, J = 1.2 Hz, 1H), 7.74-7.71(m,1H), 7.60-7.56(m, 3H),
7.48-7.40(m, 4H), 7.24-7.22(m, 1H), 6.95-6.92(m,1H), 5.40(s,
2H), 4.72(s, 2H); 13C NMR(CDCl3, 100 MHz):164.61, 145.12,
141.42, 141.09, 140.67, 137.70, 137.13, 133.75, 132.75, 130.03,
129.40, 129.18, 128.97, 128.75, 127.45, 123.55, 119.39, 118.67,
111.13, 67.44, 42.37.Mass:m/z found for C21H15N3O2 was 342.2
(M+ 1)+.
4-((6,6-Dimethyl-4-Phenyl-5,6-Dihydro-
4H-1,2-Oxazin-3-yl)Methyl)-2H-
Pyrido[3,2-b][1,4]Oxazin-3(4H)-One (5b)
Compound 5b was prepared from pyrido1,4-oxazin-3-one 3
(1 mmol), 3-(bromomethyl)-6,6-dimethyl-4-phenyl-5,6-
dihydro-4H-1,2-oxazine 4b (1.2 mmol) and combustion
derived bismuth oxide, yield 94%, melting point 67–68◦C,
Elemental analysis calculated for C20H21N3O3: C, 68.36;
H, 6.02; N, 11.96; found C, 68.29; H, 6.09; N, 12.02%; 1H
NMR(CDCl3, 400 MHz) δ: 7.95(d, 1H), 7.4-7.3(m, 5H),
7.2(d,1H), 6.9(t, 1H), 4.6(s, 2H), 4.4(s, 2H), 3.6(t,1H), 2.1-
1.8(m, 2H), 1.3(s, 6H). Mass: m/z found forC20H21N3O3 was
352.22(M+ 1)+.
4-(4-Isopropylbenzyl)-2H-Pyrido[3,2-
b][1,4]Oxazin-3(4H)-One (5c)
Compound 5c was prepared from pyrido1,4-oxazin-3-
one 3 (1 mmol),1-(bromomethyl)-4-isopropylbenzene 4c
(1.2 mmol) and combustion derived bismuth oxide, yield
93%, melting point 78–79◦C, Elemental Analysis Calculated
for C17H18N2O2: C, 72.32; H, 6.43; N, 9.92; found C,
72.25; H, 6.30; N, 10.02%; 1H NMR(CDCl3, 400 MHz)
δ:8.02-8.01 (d, J = 4.8Hz, 1H,Ar-H), 7.39-7.37(m,2H, Ar-
H), 7.20-7.12(m,3H), 6.92-6.89(m,1H), 5.31(s, 2H), 4.68(s,
2H), 2.86-2.82(m,1H), 1.20-1.18(d,6H); 13C NMR(CDCl3,
100 MHz):164.51, 147.89, 141.62, 141.03, 140.68, 134.45, 128.64,
127.41, 126.57, 126.36, 123.31, 119.15, 67.42, 42.35, 33.83,
23.95, 23.89.Mass:m/z found for C17H18N2O2 was 283.18
(M+ 1)+ .
4-(4-(Tert-Butyl)Benzyl)-2H-Pyrido[3,2-
b][1,4]Oxazin-3(4H)-One (5d)
The compound 5d was prepared from pyrido1,4-oxazin-3-
one 3 (1mmol),1-(bromomethyl)-4-(tert-butyl)benzene 4d
(1.2 mmol) and combustion derived bismuth oxide,
yield 94%, melting point 75–76◦C, Elemental analysis
calculated for C18H20N2O2: C, 72.95; H, 6.80; N, 9.45;
found C, 72.86; H, 6.71; N, 9.37%;1H NMR(CDCl3,
400 MHz) δ:8.03-8.01(d, J = 1.6 Hz, 1H), 7.40-7.38(m,2H),
7.30-7.28(m, 2H), 7.21-7.18(m,1H), 6.92-6.89(m, 1H),
5.32(s, 2H), 4.68(s, 2H), 1.26(s, 9H); 13C NMR (CDCl3,
100 MHz):164.52, 150.15, 141.63, 141.03, 140.67, 134.07,
128.35, 126.87, 126.15, 125.42, 123.33, 119.16, 67.42, 42.26,
34.42, 31.30, 31.29, 31.14; Mass:m/z found forC18H20N2O2was
297.20(M+ 1)+ .
4-(4-Nitrobenzyl)-2H-Pyrido[3,2-
b][1,4]Oxazin-3(4H)-One (5e)
Compound 5e was prepared from pyrido1,4-oxazin-3-one 3
(1mmol),1-(bromomethyl)-4-nitrobenzene 4e (1.2 mmol) and
combustion derived bismuth oxide, yield 96%, melting point 68–
69◦C, Elemental analysis calculated for C14H11N3O4: C, 58.95;
H, 3.89; N, 14.73; found C, 58.82; H, 3.77; N, 14.61%; 1H
NMR(CDCl3, 400 MHz) δ:8.14-8.12(m, 2H), 7.99-7.98(d, J = 1.6,
1H), 7.60-7.58(m, 2H), 7.26-7.23(m, 1H), 6.97-6.94(m,1H),
5.41(s, 2H), 4.72(s, 2H);13C NMR(CDCl3, 100 MHz); 164.63,
147.26, 144.42, 141.15, 141.05, 140.62, 129.29, 129.96, 123.73,
123.66, 123.59, 119.69, 67.38, 42.20;Mass: m/z found for
C14H11N3O4 286.12 (M+ 1)+.
4-((4-(4-Chlorophenyl)-6,6-Dimethyl-5,6-
Dihydro-4H-1,2-Oxazin-3-yl)
Methyl)-2H-Pyrido[3,2-b][1,4]Oxazin-
3(4H)-One (5f)
Compound 5f was prepared from pyrido1,4-oxazin-3-one
3 (1 mmol),3-(bromomethyl)-4-(4-chlorophenyl)-6,6-dimethyl-
5,6-dihydro-4H-1,2-oxazine 4f (1.2 mmol) and combustion
derived bismuth oxide, yield 95%, melting point 89–90◦C,
Elemental analysis calculated for C20H20ClN3O3: C, 62.26;
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H, 5.22; N, 10.89; found C, 62.19; H, 5.15; N, 10.79%;1H
NMR(CDCl3, 400 MHz) δ: 7.95(d, 1H), 7.4-7.2(m, 5H), 6.9(t,
1H), 4.6(s, 2H), 4.45(s, 2H), 3.6(t, 1H), 2.1-1.7(m, 2H), 1.3(s, 6H).;
Mass: m/z found forC20H20ClN3O3 was 386.17 (M+ 1)+.
4-((3-Oxo-2H-Pyrido[3,2-b][1,4]Oxazin-
4(3H)-yl)Methyl)Benzonitrile (5g)
Compound 5g was prepared from pyrido1,4-oxazin-3-one 3
(1 mmol),4-(bromomethyl)benzonitrile 4g (1.2 mmol) and
combustion derived bismuth oxide, yield 91%, melting point
59–60◦C, Elemental analysis calculated for C15H11N3O2: C,
67.92; H, 4.18; N, 15.84; found C, 67.85; H, 4.10; N, 15.75%;
1H NMR (CDCl3, 400 MHz) δ:8.0 (d, 1H), 7.7-7.6(m, 4H),
7.24(m, 1H), 7.0(d, 1H), 5.4 (s, 2H), 4.7(s, 2H); Mass: m/z found
forC15H11N3O2was 266.12 (M+ 1)+.
4-(Cyclohexylmethyl)-2H-Pyrido[3,2-
b][1,4]Oxazin-3(4H)-One (5h)
Compound 5h was prepared from pyrido1,4-oxazin-3-one
3 (1mmol),(bromomethyl)cyclohexane 4h (1.2 mmol) and
combustion derived bismuth oxide, yield 93%, melting point
60–62◦C, Elemental Analysis Calculated for C14H18N2O2: C,
68.27; H, 7.37; N, 11.37; found C, 68.18; H, 7.29; N, 11.31%;1H
NMR(CDCl3, 400 MHz) δ:8.00-7.99(d, J = 1.6Hz,1H), 7.21-
7.19(d, J = 1.6Hz, 1H), 6.92-6.89(m, 1H), 4.64(s, 2H), 4.02-4.00(d,
J = 7.2 Hz, 2H), 1.85-1.82(m, 1H), 1.69-1.57(m, 5H), 1.18-1.14(m,
3H), 1.07-1.01(m, 2H); Mass: m/z found for C14H18N2O2was
247.0(M+ 1)+ .
2-(3-(3-Oxo-2H-Pyrido[3,2-b][1,4]Oxazin-
4(3H)-yl)Propyl)Isoindoline-1,3-Dione (5i)
Compound 5i was prepared from pyrido1,4-oxazin-3-one 3
(1 mmol),2-(3-bromopropyl)isoindoline-1,3-dione 4i (1.2 mmol)
and combustion derived bismuth oxide, yield 95%, melting point
142–143◦C, Elemental Analysis Calculated for C18H15N3O4: C,
64.09; H, 4.48; N, 12.46; found C, 64.01; H, 4.40; N, 12.38%;1H
NMR(CDCl3, 400 MHz) δ: 7.9-7.8(m,3H), 7.8-7.7(m, 2H), 7.2(d,
1H), 6.9(t, 1H), 4.7(s, 2H), 4.2(t, 2H), 3.8(t, 2H), 2.2(m, 2H);
13C NMR (CDCl3, 100 MHz):168.26, 164.55, 141.41, 140.96,
140.59, 133.99, 133.79, 132.15, 123.26, 123.11, 119.08, 67.29,
47.24, 36.70, 26.83; Mass: m/z found for C18H15N3O4 was
338.1(M+ 1)+.
4-(2,6-Dichlorobenzyl)-2H-Pyrido[3,2-
b][1,4]Oxazin-3(4H)-One(5j)
Compound 5j was prepared from pyrido1,4-oxazin-3-one 3
(1 mmol),2-(bromomethyl)-1,3-dichlorobenzene 4j (1.2 mmol)
and combustion derived bismuth oxide, yield 94%, melting point
100–102◦C, Elemental Analysis Calculated for C14H10Cl2N2O2:
C, 54.39; H, 3.26; N, 9.06; found C, 54.30; H, 3.31; N, 9.01%;1H
NMR(CDCl3, 400 MHz) δ:8.0(d, 1H), 7.3-7.2(m, 3H), 7.1(d,
1H), 6.9(d, 1H), 5.6(s, 2H), 4.6 (s, 2H); Mass: m/z found for
C14H10Cl2N2O2 was 309.0(M+ 1)+ 310.0(M+ 2)+.
PHARMACOLOGY
Cell Lines
HepG2 cell line was obtained from American Type Culture
Collection. Huh-7 cell line was obtained from Japanese Collection
of Research Bioresources (JCRB) Cell Bank (Osaka, Japan) and
HCCLM3 cell line was a kind gift from Professor Zhao-You
Tang at the Liver Cancer Institute (Zhongshan Hospital, Fudan
University, Shanghai, China). All the HCC cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) with 10% FBS.
MTT Assay
The growth inhibitory activity of newly synthesized pyrido
[1,4]oxazinones against HCC cells was determined by the MTT
dye uptake method as described earlier (Baburajeev et al.,
2015). Briefly, HCC cells (2.5 × 104/ml) were incubated in
triplicate in a 96-well plate, in the presence of varying compound
concentrations at a volume of 0.2 ml, for different time intervals
at 37◦C. Thereafter, a 20 µl MTT solution (5 mg/ml in PBS) was
added to each well. After a 2 h incubation at 37◦C, a 0.1 ml
lysis buffer (20% SDS, 50% dimethylformamide) was added;
incubation was performed for 1 h at 37◦C, and the optical density
(OD) at 570 nm was measured by Tecan plate reader.
NF-κB DNA Binding Assay
Activation of NF-κB was evaluated by DNA binding assay
using TransAM NF-κB Kit according to the manufacturer’s
instructions and as previously described (Shanmugam et al.,
2011b). Briefly, 20 µg of nuclear proteins extracted from NPO
treated cells were added into 96-well plate coated with an
unlabeled oligonucleotide containing the consensus binding site
for NF-κB (5’-GGGACTTTCC-3’) and incubated for 1 h. The
wells were washed and incubated with antibodies against NF-κB
p65 subunit. An HRP conjugated secondary antibody was then
applied to detect the bound primary antibody and provided the
basis for colorimetric quantification.
NF-κB Luciferase Reporter Assay
The effect of NPO on constitutive activation of NF-κB-dependent
luciferase gene expression in HCC cells were determined
as previously described (Shanmugam et al., 2011a). NF-κB
responsive elements linked to a luciferase reporter gene were
transfected with wild-type or dominant-negative IκB. The
transfected cells were then treated with NPO for different time
points up to 24 h. Luciferase activity was measured with a Tecan
(Durham, NC, United States) plate reader and normalized to
β-galactosidase activity. All luciferase experiments were done in
triplicate and repeated twice.
Flow Cytometric Analysis
To determine the effect of NPO on cell cycle distribution,
HCCLM3 cells were treated with 10, 25 or 50 µM NPO for 48 h.
At the end of treatment period the cells were collected, washed
and fixed in ice cold 70% ethanol. The fixed cells were then
washed with 1x PBS, resuspended with 0.1% RNase A in 1× PBS
and stained with propidium iodide (25 µg/ml) [Sigma Aldrich,
Frontiers in Pharmacology | www.frontiersin.org 4 November 2018 | Volume 9 | Article 1125
fphar-09-01125 November 1, 2018 Time: 15:11 # 5
Mohan et al. Oxazinone Targets NF-κB Signaling Pathway
United States] for 30 min at room temperature. The apoptotic
Sub-G1 cell population was determined using a CyAn ADP flow
cytometer (Dako Cytomation).
Western Blot Analysis
Nuclear extracts of NPO treated or control cells were
prepared using TransAM nuclear extract kit according to
the manufacturer’s instructions and as previously described
(Shanmugam et al., 2011b). Briefly, 50 µg of nuclear proteins
extracted from NPO treated or control cells was resolved
in 10% SDS gel. After electrophoresis the proteins were
electro-transferred to a nitrocellulose membrane (Bio-Rad,
United States), blocked with Blocking One (Nacalai Tesque,
Inc., Japan), and probed with p65, pp65 and Lamin B primary
antibody overnight at 4◦C. The blot was washed, and probed
with horseradish peroxidase conjugated secondary antibody for
1 h and finally examined by chemiluminescence substrate (ECL,
GE Healthcare, United Kingdom).
Molecular Docking Analysis
To perform molecular docking, we retrieved the crystal structure
of the heterodimer complex of IκBα/NF-κB (Huxford et al., 1998)
from RCSB and used as a base our molecular docking studies.
Using the CDOCKER protocol of Discovery Studio of Accelrys
Product, we performed the molecular docking analysis to the
heterodimer complex of IκBα/NF-κB by defining all residues in
p65 within a radius of 4.5Å of any p50 atoms as binding site
(Figure 5). Further, we carried out a molecular docking run using
DS default parameters. Resulting protein-ligand complexes were
visualized using the DS visualization tool, and the analysis was
tabulated.
Acute Toxicity Studies
All animal experiments were performed according to protocols
approved by the Sing Health Institutional Animal Use and
Care Committee. For acute toxicity study, eight week-old NCr
nude Female mice (In vivos, Singapore) were treated with
intra-peritoneal injections of 5 mg/kg, 25 mg/kg, 50 mg/kg,
of NPO and vehicle (0.1% DMSO). The mice were monitored
daily, for development of any toxic signs, including change
in physical appearance, hunched back, increased respiration,
arching and rolling, muscle spasm, tremors, cyanosis, stimulation
or depression. The changes in body weight, food and water
intakes were monitored daily for up to day 8. On day 8, cardiac
puncture was employed for terminal blood collection from the
mice. The liver and kidney functions were determined using the
serum collected. ALT (SGPT) as well as AST (SGOT) were used
to assess liver functions and BUN was used to evaluate kidney
function as described previously (Dai et al., 2017).
Orthotopic implantation of HCC in SCID
Mice
HCCLM3 cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine. HCCLM3-
luciferase (HCCLM3-Luc) cells were generated by transfecting
HCCLM3 cells with the firefly luciferase (FLUC) gene. 100 µl
medium containing 3 × 106 HCCLM3-Luc cells were injected
subcutaneous in the right flank of nude mice. When the tumor
volume reached approximately 1 cm3, tumor was harvested, cut
into 2 mm3 pieces and implanted orthotopically into the liver of
Female NCr nude mice. A midline abdominal incision (3–5 cm)
was made to expose the whole liver and the liver capsule was
mechanically injured with a needle. Then a piece of HCC tissue
(about 2 mm3) was filled into the liver of the recipient mouse
with forceps and the abdominal wall closed. The skin incisions
were closed with wound clips. The development of tumors was
monitored by measuring the bioluminescence signals and was
quantified using the Xenogen IVIS system (Caliper Life Sciences,
CA, United States) as described previously (Dai et al., 2017).
Orthotopic HCC Tumor Model
All animal experiments were performed according to protocols
approved by the SingHealth Institutional Animal Use and Care
Committee. For drug efficacy study, eight week-NCr nude Female
mice (Invivos, Singapore) were implanted orthotopically with
HCCLM3-Luc cells-induced tumors. When the bioluminescence
signal reaches 106, mice were grouped into 2 groups and treated
with vehicle (0.1% DMSO) and 50 mg/kg of NPO, twice a
week by intra-peritoneal injections for 4 consecutive weeks. The
development of tumor was monitored twice a week by measuring
the bioluminescence signals. Mice were euthanized when the
humane end-point criteria is met by CO2 inhalation. Primary
tumor (liver) and lung tissues were excised, snap-frozen and
stored at –80◦C until used for experiments.
Statistical Analysis
Student t-test was used to analyze the data. For in vivo
studies, unpaired t-test with Welch’s correction was used for
FIGURE 1 | Schematic representation for the synthesis of N-substituted pyrido1,4-oxazin-3-ones.
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TABLE 1 | Library of synthesized N-substituted pyrido-1,4-oxazin-3-ones.
Entry Pyrido1,4-Oxazin-3-one (3) Benzyl halide
4(a-j)
Product 5(a-j) HepG2 IC50 (µM)
5a <50
5b <50
5c 35.1 ± 3.5
5d <50
5e 20.3 ± 2.1
5f 37.2 ± 4.9
5g 40.2 ± 2.5
(Continued)
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TABLE 1 | Continued
Entry Pyrido1,4-Oxazin-3-one (3) Benzyl halide
4(a-j)
Product 5(a-j) HepG2 IC50 (µM)
5h 46.1 ± 4.0
5i 28.2 ± 1.1
5j 44.6 ± 3.4
Paclitaxel 4.1 ± 0.3
statistical comparisons between groups. p < 0.05 was considered
statistically significant (GraphPad Prism 5.0; GraphPad Software,
CA, United States).
RESULTS
Chemistry
In the present report, we report the synthesis of N-substituted
pyrido-1,4-oxazin-3-ones. Initially, 2-aminopyridine-3-ol (1)
was allowed to react with chloro acetylchloride (2) at 5◦C in
basic medium to yield 2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
(3). Next, we prepared N-substituted pyrido1,4-oxazin-3-ones
(5a-j, Table 1) by reacting 3 with various alkyl bromides (4a-j)
in the presence of combustion derived bismuth oxide in DMF
solvent (Figure 1). The compounds obtained were characterized
by melting point, 1H NMR, 13C NMR, elemental and mass
spectral analysis. Detailed chemical characterizations of the newly
synthesized compounds are provided in experimental section and
chromatograms are provided in Supplementary File.
Pharmacology
Growth Inhibitory Activity of N-Substituted
Pyrido-1,4-Oxazin-3-Ones Against HCC Cells
The library of synthesized N-substituted pyrido-1,4-oxazin-3-
ones were tested for their growth inhibitory activity against
HepG2 cells using MTT assay, the results are summarized
in Table 1. Among the tested compounds, the compound 5e
(NPO) significantly inhibited the proliferative activity of HepG2
cells, with an IC50 values of 20.3 µM. The presence of nitro
group in phenolic ring was found to be potent antiproliferative
agent against HepG2 cells. The N-substituted pyrido 1,4-oxazines
bearing chlorine atom and nitrile group were not notably effective
and the incorporation of methyl groups and isopropyl group
to phenyl ring diminishes its potency as noted regarding the
compounds 5c and 5d. Further, introduction of isoindoline-1,3-
dione group (5i) on pyrido1,4-oxazine resulted a moderately
enhanced inhibition with an IC50 value of 28.2 µM. We next
examined the effect of NPO on the viability of panel of HCC
(HepG2, HCCLM3, and Huh-7) cells in different dose and
time points (Figure 2). We observed significant reduction in
the viability cells on treatment with NPO in time- and dose-
dependent manner.
NPO Abrogates Constitutive Activation of NF-κB in
HCC Cells
Oh and coworkers performed high-throughput screening
of most diverse 7,243 compounds using time-resolved
fluorescence resonance energy transfer and identified
three scaffolds namely 7-benzoyl-4-phenylcyclopenta[1,2]
oxazine, 1-(thiophen or furan)-2,3-dihydroimidazo[1,5]
pyridine and 2-phenyloxazolo[5,4] pyridine as potent IKKβ
inhibitors, and in turn disrupts NF-κB signaling pathway
(Oh et al., 2010). Therefore, we evaluated the effect of
lead pyrido-oxazinone, NPO on constitutive activation
of NF-κB in HepG2, HCCLM3, and Huh-7 cells. The
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FIGURE 2 | (A–C) NPO the lead compound significantly inhibits the viability of various HCC cells lines. NPO was identified as lead anticancer agent among the
structural variants and NPO decreased the growth of HepG2, HCCLM3 and Huh-7 cells in dose- and time-dependent manner. (D) and (E), NPO can induce
apoptosis in a dose and time-dependent manner in HCCLM3 cells. ∗p < 0.05.
treatment of HCC cells with NPO at different time points
(0, 12, 18, and 24 h) suppressed the persistent activation
of NF-κB in HCC cells in a time-dependent manner
(Figure 3).
NPO Induces Increased Accumulation of Cells in the
Sub-G1 Phase of the Cell Cycle
Results from the flow cytometry analysis clearly indicated that the
NPO induces accumulation of cells in the sub-G1 phase which
is indicative of apoptosis in a dose and time-dependent manner
(Figures 2D,E). Taken together, these data suggest that NPO is a
potent inducer of apoptosis in HCC cells.
NPO Inhibits NF-κB Dependent Luciferase
Expression in HCC Cells
Transcription is a multifactorial process and suppression of DNA
binding activity of NF-κB alone does not always correspond to the
inhibition of its transcriptional activity. Therefore, we transfected
HepG2, HCCLM3, and Huh-7 cells as described in methods and
evaluated the effect of NPO on the NF-κB dependent luciferase
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FIGURE 3 | (A–C) NPO downregulates NF-κB DNA binding ability in HCC
cells. HepG2, HCCLM3, and Huh-7 cells were treated with NPO for different
time points, nuclear extracts were prepared, and 20 µg of nuclear extract
protein was used for DNA binding assay. The NF-κB DNA binding was
inhibited in time-dependent manner. (D) Effect of NPO on p65
phosphorylation in HCCLM3 cells. Nuclear extracts were prepared as
described in Materials and Methods. HCCLM3 cells were treated with NPO at
doses of 10, 25, and 50 µM for 24 h and expression of various proteins was
analyzed by western blot analysis. ∗p < 0.05.
expression. The treatment of HCC cells with NPO reduced
NF-κB regulated reporter gene expression in a time-dependent
manner with the maximum inhibition of nearly 50% (Figure 4).
These results demonstrate that NPO reduces DNA binding ability
of NF-κB and in turn downregulates NF-κB regulated gene
expression.
FIGURE 4 | NPO inhibits NF-κB dependent luciferase expression in HCC
cells: with NF-κB responsive elements linked to a luciferase gene were
transfected with wild-type or dominant-negative IκB and transfected (A)
HepG2, (B) HCCLM3, and (C) Huh-7 cells were treated with NPO at indicated
time points and reporter (luciferase) activity was measured. All luciferase
experiments were done in triplicate and repeated twice (∗p < 0.05).
NPO Decreases p65 Phosphorylation in HCC Cells
We next investigated the effect of NPO on p65 phosphorylation
in HCC cells. The data reveals that NPO can indeed abrogate p65
phosphorylation in a dose dependent manner in HCCLM3 cells
(Figure 3D).
In silico Interaction of NPO With NF-κB
In order to understand the molecular interaction of NPO
within the heterodimeric complex of IκBα/NF-κB, the molecular
docking simulations of the reported compounds were performed
using CDOCKER program (Wu et al., 2003). We used the
crystal structure of heterodimer of IκBα and NF-κB (PDB
ID: 1IKN). Using the CDOCKER protocol of Accelrys DS
Version 2.5, we performed the molecular docking studies. All
the compounds were well docked into the interface of the
heterodimeric complex of NF-κB. Analysis of the results shows
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FIGURE 5 | Molecular interactions between NPO and the IκBα/NF-κB
complex. (A) Molecular docking solution for NPO (in stick representation, and
atomic coloring with orange) targeting IκBα/NF-κB complex. The p50 sub-unit
is show in orange, p65 in cyan, and IκBα in green; (B) the interaction map of
the complex formed between NPO and IκBα/NF-κB complex is shown.
that NPO orient into the p65 interaction region of IκBα,
which comprises of amino acids like Gln249, Tyr248, Glu287,
Ser288, Tyr289, Asp290, Thr291, and Pro281 with a variety
of interactions (Figure 5). Further, the condensed pyrido-1,4-
oxazin-3-one ring of NPO buried into the hydrophobic pocket
made up of Val244, Ala242, His245, and Lys221 of the p65
subunit of NF-κB. The ring was presented to interact with Arg246
of P65 subunit and Tyr251 of IκBα on the other side via hydrogen
bonding indicates that preferential binding of NPO to NF-κB
complex.
NPO Treatment Did Not Induce Adverse Effects
in vivo
We initially performed acute toxicity studies with NPO to
determine its sub-lethal dose for in vivo studies. The mice were
monitored for 8 days after the intraperitoneal administration
of the 5, 25, or 50 mg/kg dose of NPO and vehicle (0.1%
DMSO). At the end of the experiment, no mortality was observed,
which indicated that the LD50 must be higher than 50 mg/kg.
As indicated in the Figures 6A–C, there was no significant
difference of behavioral and physical symptoms such as body
weight, feed consumption, and water intake between NPO treated
and the control group. The various biochemical parameters of
the serum including alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and blood urea nitrogen (BUN) were
detected by the autoanalyzer. It was noted that compared to the
control group, no substantial differences were found in the serum
levels of ALT, AST, and BUN in the NPO-treated groups. All
these results indicate that the intraperitoneal administration of
NPO did not produce any obvious toxic effects in NCr nude mice
(Figures 6D–F).
NPO Inhibited Tumor Growth in an Orthotopic HCC
Mouse Model
We also analyzed the anti-tumor potential of NPO in vivo
through intraperitoneal administration using the HCCLM3_Luc
orthotopic model. After treatment with 50 mg/kg of NPO
(three doses per week for 4 consecutive weeks), bioluminescence
images revealed that there was a significant reduction of tumor
growth in the NPO group compared with the vehicle control
group at the end of the assay (Figure 7A). The differences
in tumor burden at the last time point was quantitated
by measuring photon counts and expressed as the tumor
burden relative to photon counts before the first therapeutic
injection. An unpaired t test with Welch’s correction indicated
that the NPO treatment group had significant inhibition of
tumor burden compared with the vehicle-treated controls
(Figure 7B).
DISCUSSION AND CONCLUSION
NF-κB has been reported to be persistently activated in several
types of cancer including solid (breast and prostate) tumors
and hematopoietic (multiple myeloma, chronic myelogenous
leukemia, acute myelogenous leukemia, acute lymphocyte
leukemia) tumors which render it as an important molecular
therapeutic target in designing novel anti-cancer therapeutics
(Nakshatri et al., 1997; Feinman et al., 1999; Palayoor et al.,
1999; Kordes et al., 2000; Griffin, 2001; Aggarwal, 2004). NF-κB
regulates the expression of various oncogenic genes and plays
a crucial role in regulation of inflammation, stress response
and immune system. Dysregulation of NF-κB signaling can
promote neoplastic transformation, cancer progression and
tumor evasion (Plati et al., 2008). Hence researchers have rightly
labeled the activation of NF-κB as the enemy within the cell
(Aggarwal).
Prior studies have also established the presence of NF-κB
proteins in advanced ovarian cancers and its association with
poor overall survival (Annunziata et al., 2010). Analysis of
NF-κB in clear cell renal cell carcinoma tissues revealed the
expression of NF-κB in 85% of patient tissues and thereby
presented NF-κB as a potential therapeutic target in the
treatment of clear cell renal cell carcinoma (Meteoglu et al.,
2008). Li and coworkers reported the possible involvement
of IL-17A induced NF-κB activation in metastasis and poor
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FIGURE 6 | Acute toxicity studies with NPO. (A) The effect of intraperitoneal administration of NPO on body weight change. The nude mice were treated with one
single dose of NPO (5, 25, or 50 mg/kg). Error bars are means ± SD. Ordinary one-way ANOVA. (B,C) The effect of NPO on mice behavior study including feed
consumption (B) and water intake (C). Error bars are means ± SD. Ordinary one-way ANOVA. (D–F) Effect of NPO on biochemical parameters such as ALT, AST,
and BUN levels. Error bars are means ± SD. Ordinary one-way ANOVA.
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FIGURE 7 | NPO significantly abrogates tumor growth in an orthotopic mouse model. (A) Bioluminescence images of orthotopic tumor bearing mice. Ncr nude mice
were orthotopically implanted with HCCLM3_Luc cells and then treated with 0.1% DMSO (n = 8) or 50 mg/kg NPO (n = 8) for 26 days. (B) The scatter plot
represents the differences in tumor burden between control and NPO treated mice and is expressed as tumor burden relative to photon counts. The statistics was
determined using unpaired t test with Welch’s correction. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
prognosis of HCC (Li et al., 2011). In the present study,
we have prepared a novel class of pyrido-1,4-oxazin-3-ones
and identified the lead anticancer structure against HCC
cells.
This study introduces a novel N-alkylation procedure
to prepare N-substituted pyrido-1,4-oxazin-3-ones. Functional
studies further suggested that lead compound can interfere
with DNA binding ability of NF-κB and may inhibit relay of
downstream signaling and in turn can modulate the expression
of NF-κB regulated genes.
Additionally, the preclinical safety and efficacy of NPO was
further confirmed using nude mice. It was noted that no
obvious toxicity was observed after treatment with NPO at
5 mg/kg, 25 mg/kg and 50 mg/kg by intraperitoneal injections.
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Interestingly, we also found that NPO at a dose of 50 mg/kg could
significantly attenuate tumor growth in an orthotopic mouse
model. Overall, these findings establish the potential role of NPO
as a novel NF-κB blocker that can find suitable application for the
treatment of diverse malignancies.
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DATA SHEET S1 | Effect of NPO on p65 and pp65 phosphorylation in HCCLM3
cells. Nuclear extracts were prepared as described in Materials and Methods.
HCCLM3 cells were treated with NPO at doses of 10, 25, and 50 mM and
expression of various proteins was analyzed by western blot analysis.
DATA SHEET S2 | NPO can induce apoptosis in a dose dependent manner in
HCCLM3 cells.
DATA SHEET S3 | NPO can induce apoptosis in a time-dependent manner in
HCCLM3 cells.
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